Cue Biopharma, Inc. Operating Income
Cue Biopharma, Inc. (CUE) reported Operating Income of -$87.69 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-14
- Cue Biopharma, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$87.69M.
- Cue Biopharma, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$5.35M.
- Cue Biopharma, Inc. operating income (loss) for the quarter ending 2025-12-31 was $1.98M.
- Cue Biopharma, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$7.59M.
- Cue Biopharma, Inc. operating income (loss) for fiscal 2025 was -$26.55M.
- Cue Biopharma, Inc. operating income (loss) for fiscal 2024 was -$41.50M.
- Cue Biopharma, Inc. operating income (loss) for fiscal 2023 was -$52.15M.
- Cue Biopharma, Inc. operating income (loss) for fiscal 2022 was -$53.23M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$87.69M 10-Q · filed 2026-08-14 | -$93.05M 10-Q · filed 2026-08-14 | -$91.07M derived: sum of 3 quarters · filed 2026-08-14 | -$98.67M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | -$5.35M 10-Q · filed 2026-05-14 | -$3.38M derived: sum of 2 quarters · filed 2026-05-14 | -$10.97M derived: sum of 3 quarters · filed 2026-05-14 | -$19.61M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | $1.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$5.62M derived: sum of 2 quarters · filed 2026-03-16 | -$14.25M derived: sum of 3 quarters · filed 2026-08-14 | -$26.55M 10-K · filed 2026-03-16 | |
| 2025-09-30 | -$7.59M 10-Q · filed 2025-11-12 | -$16.23M derived: sum of 2 quarters · filed 2026-08-14 | -$28.53M 10-Q · filed 2025-11-12 | -$38.16M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | -$8.63M 10-Q · filed 2026-08-14 | -$20.93M 10-Q · filed 2026-08-14 | -$30.57M derived: sum of 3 quarters · filed 2026-08-14 | -$39.38M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | -$12.30M 10-Q · filed 2026-05-14 | -$21.93M derived: sum of 2 quarters · filed 2026-05-14 | -$30.75M derived: sum of 3 quarters · filed 2026-05-14 | -$41.13M derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | -$9.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$18.45M derived: sum of 2 quarters · filed 2026-03-16 | -$28.83M derived: sum of 3 quarters · filed 2026-03-16 | -$41.50M 10-K · filed 2026-03-16 | |
| 2024-09-30 | -$8.81M 10-Q · filed 2025-11-12 | -$19.20M derived: sum of 2 quarters · filed 2025-11-12 | -$31.87M 10-Q · filed 2025-11-12 | -$45.70M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | -$10.38M 10-Q · filed 2025-08-12 | -$23.05M 10-Q · filed 2025-08-12 | -$36.88M derived: sum of 3 quarters · filed 2025-08-12 | -$48.30M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | -$12.67M 10-Q · filed 2025-05-12 | -$26.50M derived: sum of 2 quarters · filed 2025-05-12 | -$37.92M derived: sum of 3 quarters · filed 2025-05-12 | -$51.44M derived: sum of 4 quarters · filed 2025-05-12 | |
| 2023-12-31 | -$13.83M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$25.25M derived: sum of 2 quarters · filed 2025-03-31 | -$38.77M derived: sum of 3 quarters · filed 2025-03-31 | -$52.15M 10-K · filed 2025-03-31 | |
| 2023-09-30 | -$11.42M 10-Q · filed 2024-11-14 | -$24.94M derived: sum of 2 quarters · filed 2024-11-14 | -$38.32M 10-Q · filed 2024-11-14 | -$53.18M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | -$13.52M 10-Q · filed 2024-08-14 | -$26.90M 10-Q · filed 2024-08-14 | -$41.76M derived: sum of 3 quarters · filed 2024-08-14 | -$52.79M derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | -$13.38M 10-Q · filed 2024-05-09 | -$28.25M derived: sum of 2 quarters · filed 2024-05-09 | -$39.28M derived: sum of 3 quarters · filed 2024-05-09 | -$52.37M derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | -$14.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$25.90M derived: sum of 2 quarters · filed 2024-03-28 | -$38.99M derived: sum of 3 quarters · filed 2024-03-28 | -$53.23M 10-K · filed 2024-03-28 | -$53.22M 10-K · filed 2023-03-21 |
| 2022-09-30 | -$11.03M 10-Q · filed 2023-11-03 | -$24.12M derived: sum of 2 quarters · filed 2023-11-03 | -$38.36M 10-Q · filed 2023-11-03 | -$46.25M derived: sum of 4 quarters · filed 2023-11-03 | |
| 2022-06-30 | -$13.09M 10-Q · filed 2023-08-08 | -$27.33M 10-Q · filed 2023-08-08 | -$35.22M derived: sum of 3 quarters · filed 2023-08-08 | -$48.24M derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | -$14.24M 10-Q · filed 2023-05-09 | -$22.13M derived: sum of 2 quarters · filed 2023-05-09 | -$35.15M derived: sum of 3 quarters · filed 2023-05-09 | -$45.45M derived: sum of 4 quarters · filed 2023-05-09 | |
| 2021-12-31 | -$7.89M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | -$20.91M derived: sum of 2 quarters · filed 2023-03-21 | -$31.21M derived: sum of 3 quarters · filed 2023-03-21 | -$43.71M 10-K · filed 2023-03-21 | |
| 2021-09-30 | -$13.02M 10-Q · filed 2022-11-14 | -$23.32M derived: sum of 2 quarters · filed 2022-11-14 | -$35.82M 10-Q · filed 2022-11-14 | -$46.81M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | -$10.30M 10-Q · filed 2022-08-04 | -$22.82M 10-Q · filed 2022-08-04 | -$33.80M derived: sum of 3 quarters · filed 2022-08-04 | -$43.93M derived: sum of 4 quarters · filed 2022-08-04 | |
| 2021-03-31 | -$12.52M 10-Q · filed 2022-05-10 | -$23.49M derived: sum of 2 quarters · filed 2022-05-10 | -$33.62M derived: sum of 3 quarters · filed 2022-05-10 | -$44.57M derived: sum of 4 quarters · filed 2022-05-10 | |
| 2020-12-31 | -$10.97M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | -$21.11M derived: sum of 2 quarters · filed 2022-03-16 | -$32.05M derived: sum of 3 quarters · filed 2022-03-16 | -$45.04M 10-K · filed 2022-03-16 | |
| 2020-09-30 | -$10.13M 10-Q · filed 2021-11-09 | -$21.07M derived: sum of 2 quarters · filed 2021-11-09 | -$34.07M 10-Q · filed 2021-11-09 | -$43.08M derived: sum of 4 quarters · filed 2021-11-09 | |
| 2020-06-30 | -$10.94M 10-Q · filed 2021-08-09 | -$23.94M 10-Q · filed 2021-08-09 | -$32.95M derived: sum of 3 quarters · filed 2021-08-09 | -$40.05M derived: sum of 4 quarters · filed 2021-08-09 | |
| 2020-03-31 | -$12.99M 10-Q · filed 2021-05-10 | -$22.01M derived: sum of 2 quarters · filed 2021-05-10 | -$29.10M derived: sum of 3 quarters · filed 2021-05-10 | -$38.34M derived: sum of 4 quarters · filed 2021-05-10 | |
| 2019-12-31 | -$9.02M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | -$16.11M derived: sum of 2 quarters · filed 2021-03-09 | -$25.34M derived: sum of 3 quarters · filed 2021-03-09 | -$36.77M 10-K · filed 2021-03-09 | |
| 2019-09-30 | -$7.09M 10-Q · filed 2020-11-09 | -$16.32M derived: sum of 2 quarters · filed 2020-11-09 | -$27.75M 10-Q · filed 2020-11-09 | -$38.72M derived: sum of 4 quarters · filed 2020-11-09 | |
| 2019-06-30 | -$9.23M 10-Q · filed 2020-08-07 | -$20.66M 10-Q · filed 2020-08-07 | -$31.62M derived: sum of 3 quarters · filed 2020-08-07 | -$44.38M derived: sum of 4 quarters · filed 2020-08-07 | |
| 2019-03-31 | -$11.43M 10-Q · filed 2020-05-07 | -$22.39M derived: sum of 2 quarters · filed 2020-05-07 | -$35.15M derived: sum of 3 quarters · filed 2020-05-07 | -$42.62M derived: sum of 4 quarters · filed 2020-05-07 | |
| 2018-12-31 | -$10.97M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$23.73M derived: sum of 2 quarters · filed 2020-03-12 | -$31.20M derived: sum of 3 quarters · filed 2020-03-12 | -$38.70M 10-K · filed 2020-03-12 | |
| 2018-09-30 | -$12.76M 10-Q · filed 2019-11-07 | -$20.23M derived: sum of 2 quarters · filed 2019-11-07 | -$27.73M 10-Q · filed 2019-11-07 | -$38.19M derived: sum of 4 quarters · filed 2019-11-07 | |
| 2018-06-30 | -$7.47M 10-Q · filed 2019-08-08 | -$14.98M 10-Q · filed 2019-08-08 | -$25.43M derived: sum of 3 quarters · filed 2019-08-08 | -$30.46M derived: sum of 4 quarters · filed 2019-08-08 | |
| 2018-03-31 | -$7.52M 10-Q · filed 2019-05-08 | -$17.96M derived: sum of 2 quarters · filed 2019-05-08 | -$22.99M derived: sum of 3 quarters · filed 2019-05-08 | -$27.41M derived: sum of 4 quarters · filed 2019-05-08 | |
| 2017-12-31 | -$10.44M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | -$15.47M derived: sum of 2 quarters · filed 2019-03-14 | -$19.88M derived: sum of 3 quarters · filed 2019-03-14 | -$23.23M 10-K · filed 2019-03-14 | |
| 2017-09-30 | -$5.03M 10-Q · filed 2018-11-13 | -$9.45M derived: sum of 2 quarters · filed 2018-11-13 | -$12.79M 10-Q · filed 2018-11-13 | ||
| 2017-06-30 | -$4.41M 10-Q · filed 2018-08-13 | -$7.76M 10-Q · filed 2018-08-13 | |||
| 2017-03-31 | -$3.35M 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |